JP2022546456A - 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン - Google Patents

自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン Download PDF

Info

Publication number
JP2022546456A
JP2022546456A JP2022513372A JP2022513372A JP2022546456A JP 2022546456 A JP2022546456 A JP 2022546456A JP 2022513372 A JP2022513372 A JP 2022513372A JP 2022513372 A JP2022513372 A JP 2022513372A JP 2022546456 A JP2022546456 A JP 2022546456A
Authority
JP
Japan
Prior art keywords
esketamine
patient
suicide
treatment
soc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546456A5 (https=
Inventor
エム． カヌソー，カーラ
フー，ドン－ジン
エフ． アイオネスキュー，ドーン
レーン，ロシアンヌ
Original Assignee
ヤンセン ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカルズ，インコーポレーテッド filed Critical ヤンセン ファーマシューティカルズ，インコーポレーテッド
Publication of JP2022546456A publication Critical patent/JP2022546456A/ja
Publication of JP2022546456A5 publication Critical patent/JP2022546456A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2022513372A 2019-08-28 2020-08-28 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン Pending JP2022546456A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962892841P 2019-08-28 2019-08-28
US62/892,841 2019-08-28
US201962897593P 2019-09-09 2019-09-09
US62/897,593 2019-09-09
PCT/IB2020/058030 WO2021038500A2 (en) 2019-08-28 2020-08-28 Esketamine for the treatment of patients with major depressive disorder, including suicidality

Publications (2)

Publication Number Publication Date
JP2022546456A true JP2022546456A (ja) 2022-11-04
JP2022546456A5 JP2022546456A5 (https=) 2023-09-04

Family

ID=74685267

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022513372A Pending JP2022546456A (ja) 2019-08-28 2020-08-28 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン

Country Status (5)

Country Link
US (1) US20220304950A1 (https=)
EP (1) EP4021432A4 (https=)
JP (1) JP2022546456A (https=)
CN (1) CN114286674A (https=)
WO (1) WO2021038500A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2907692T3 (es) 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
AU2022283967A1 (en) * 2021-06-03 2024-01-18 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
WO2025057111A1 (en) * 2023-09-12 2025-03-20 Clexio Biosciences Ltd. Esketamine or a pharmaceutical salt thereof for use in a method of treating major depressive disorder
WO2025256585A1 (zh) * 2024-06-12 2025-12-18 江苏恩华药业股份有限公司 R-氯胺酮在治疗伴急性自杀意念或行为的抑郁症中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
JP2009515952A (ja) * 2005-11-18 2009-04-16 アストラゼネカ・アクチエボラーグ 制御放出性製剤のクエチアピン
WO2016172672A1 (en) * 2015-04-24 2016-10-27 Icahn School Of Medicine At Mount Sinai Method for treating suicidal ideation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
DE10306686A1 (de) 2003-02-12 2004-08-26 Ing. Erich Pfeiffer Gmbh Austragvorrichtung zur manuellen Erzeugung eines Volumenstroms
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
FR3003481B1 (fr) 2013-03-19 2020-05-15 Aptar France Sas Dispositif de distribution de produit fluide.
AU2015318123A1 (en) * 2014-09-15 2017-03-30 Janssen Pharmaceutica Nv Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
US20160338977A1 (en) * 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
KR20240011237A (ko) * 2017-12-22 2024-01-25 얀센 파마슈티카 엔브이 우울증 치료를 위한 에스케타민

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
JP2009515952A (ja) * 2005-11-18 2009-04-16 アストラゼネカ・アクチエボラーグ 制御放出性製剤のクエチアピン
WO2016172672A1 (en) * 2015-04-24 2016-10-27 Icahn School Of Medicine At Mount Sinai Method for treating suicidal ideation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CARLA M. ET AL.: "Efficacy and Safety of Intranasal Esketamine for theRapid Reduction of Symptoms of Depression andSui", AM. J. PSYCHIATRY, vol. 175, 7, JPN7024004685, pages 620 - 630, ISSN: 0005677384 *
ELIAS AJUB ET AL.: "Efficacy of Esketamine in the Treatment of Depression With Psychotic Features: A Case Series", BIOLOGICAL PSYCHIATRY, vol. 83, 1, JPN6024044409, 2018, pages 15 - 16, ISSN: 0005677383 *
SHIGENOBU KANBA ET AL.: "Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012", PSYCHIATRY AND CLINICAL NEUROSCIENCES, vol. 67, JPN6024044410, 2013, pages 285 - 300, ISSN: 0005677386 *
日本うつ病学会治療ガイドライン I.双極性障害 2020, JPN7024004686, ISSN: 0005677385 *

Also Published As

Publication number Publication date
CN114286674A (zh) 2022-04-05
US20220304950A1 (en) 2022-09-29
WO2021038500A2 (en) 2021-03-04
WO2021038500A3 (en) 2021-04-22
EP4021432A4 (en) 2023-08-16
EP4021432A2 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
TWI843711B (zh) 用於治療憂鬱症的艾司氯胺酮（ｅｓｋｅｔａｍｉｎｅ）
US11883526B2 (en) Esketamine for the treatment of depression
JP2022546456A (ja) 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン
US20200009081A1 (en) Delivery Of Esketamine For The Treatment Of Depression
CA3153856A1 (en) Intranasal administration of esketamine
AU2021388141A1 (en) Treatment of raynaud's disease
JP2025502098A (ja) うつ病の治療のための組成物及び方法
JP7840873B2 (ja) うつ病の治療方法
JP2019073493A (ja) ヴルヴォディニアの治療
WO2024196949A1 (en) Treatment of scleroderma
HK40010199A (en) Esketamine for the treatment of depression
HK40107870A (zh) 用於治疗抑郁症的艾司氯胺酮

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230825

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260105